RecruitingNCT05839418
Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)
Sponsor
Erasme University Hospital
Enrollment
3,000 participants
Start Date
Mar 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults admitted fir SE treatment in each of the participating centers and to identify predictors of outcome and refractoriness.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients aged 18 years or above
- Patients admitted for management of Status Epilepticus as their primary diagnosis
- Patients admitted for another primary diagnosis but identified with Status Epilepticus during their acute hospital stay
Exclusion Criteria1
- \- Patients with post-cardiac arrest SE
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05839418
Related Trials
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
NCT0690717351 locations
Improving Status Epilepticus Treatment Times
NCT061947471 location
Augmented Renal Clearance in Neurocritical Care
NCT074106243 locations
Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
NCT0575662110 locations
Simulation Trial of Telemedical Support for Paramedics
NCT064417604 locations